Using RNA ®ngerprinting (RAP) strategy and Northern blot analysis, we identi®ed a dierentially expressed sequence DOC-2 which is detectable in all normal human ovarian surface epithelial (HOSE) cell cultures but not in ovarian cancer cell lines and tissues. Subsequent cloning of DOC-2 from a cDNA library generated from the HOSE cells was carried out using the 3' and 5' RACE approach. A 3268 base pair full length cDNA of DOC-2 was isolated and sequenced. The predicted protein has a length of 770 amino acids. Homology search of all NCBI sequences indicated that the amino acid sequence of DOC-2 shares 93% homology with the mouse p96/ mDab2 phosphoprotein and has a phosphotyrosine interacting domain (PID) and multiple SH3 binding motifs. Chromosomal localization by FISH showed that the DOC-2 gene is located on 5p13. Western blot analysis showed that the 105 kDa DOC-2 protein was down-regulated in all the carcinoma cell lines. In-situ immunohistochemistry performed on normal ovaries, and benign, borderline and invasive ovarian tumor tissues showed down regulation of DOC-2 protein particularly in serous ovarian tumor tissues. When DOC-2 was transfected into the ovarian carcinoma cell line SKOV3, the stable transfectants showed signi®cantly reduced growth rate and ability to form tumors in nude mice. These data suggest that down-regulation of DOC-2 may play an important role in ovarian carcinogenesis.
Introduction
Ovarian cancer is the fourth leading cause of death from cancers among American women after lung, breast and colon cancers. Ovarian cancer of epithelial origin, which constitutes more than 90% of the disease, is the most lethal among all gynecological malignancies. The overall 5-year survival rate is only about 30% (Piver et al., 1992) . The poor prognosis is mainly due to the lack of sensitive tests for detection of the early stage of the disease, which is often asymptomatic. At the time of diagnosis, about 70% of patients have cancer cells spread to the pelvic and abdominal viscera or developed distant metastasis (Stage III/IV). Common epithelial ovarian cancers are thought to develop from the surface epithelium of the ovary, which shares the same developmental origin (coelomic epithelium) with the general pelvic and abdominal peritoneum. We and other laboratories have demonstrated that common epithelial ovarian cancer is of unifocal origin (Jacobs et al., 1992; Mok et al., 1993a; Tsao et al., 1993) suggesting that early stages of the disease can be detected if speci®c tumor markers expressed at early stages can be identi®ed.
Ovarian carcinogenesis is believed to be a multi-step process, involving multiple genetic changes. The malignant properties of ovarian cancer cells are the manifestation of underlying changes in gene expression which may arise by either of two mechanisms: (1) by mutation, deletion of rearrangement, leading to disruption or loss of coding information; (2) by transcriptional, post-transcriptional, translational, or post-translational up-or down-regulation. On these bases, genes with altered expression belong to either one of the two categories. Class one genes comprise genes with coding changes, which results from deletion or mutation along the genes. Examples are the p53 tumor suppressor gene (Tsao et al., 1991; Okamoto et al., 1991; Marks et al., 1991; Mok et al., 1993a) and the K-ras oncogene (Filmus and Buick 1985 ; Van't Veer et al., 1988; Enomoto et al., 1991; Mok et al., 1993b) . Class two genes are those with intact coding regions, whose expression is up-or down-regulated in ovarian cancer cells compared with their normal progenitors. They should be much more prevalent than class I genes, probably because they arise as clusters of down stream genes, under regulation of individual class one genes, either directly or indirectly, in a regulatory cascade. Thus, selecting at the messenger RNA level makes immediately available the altered genes responsible for the altered phenotype of the ovarian cancer cells. These genes can be utilized directly as candidate ovarian tumor markers, even before their functional roles have been delineated.
Current methods used to distinguish messenger RNAs in comparative studies rely largely on subtractive hybridization or dierential hybridization techniques, which involve long and tedious screening procedures, and they can screen only a limited population of RNAs simultaneously. With the modi®cation of DNA technology, consistent ®ngerprint patterns can be generated from either total or messenger RNAs using arbitrarily designed primers (Liang and Pardee 1992; Welsh et al., 1992) . We have adapted the RNA ®ngerprinting or the RAP stragegy to identify dierentially expressed RNAs in epithelial ovarian cancer cells (Wong et al., 1993; Mok et al., 1994) . Using this strategy, we identi®ed a partial cDNA called DOC-2. Using this cDNA fragment for Northern blot analysis on normal human ovarian surface epithelial cells (HOSE), ovarian carcinoma cell lines and tissues, two transcripts with sizes 3.7 kb and 2.9 kb were observed in all the normal HOSE cell cultures but not in any of the ovarian carcinoma cell lines and tissues (Wong et al., 1993; Mok et al., 1994) . Here, we report the cloning of the full-length DOC-2 cDNA. Transfection experiments have also been performed to evaluate its tumor suppressor role in human epithelial ovarian cancer. We suggest that DOC-2 may play an important role in ovarian cancer development.
Results

Identi®cation of the full-length DOC-2 cDNA
Using the 5' and 3' RACE cloning strategy and subsequent DNA sequencing, we identi®ed a complete DOC-2 cDNA fragment with 3268 bp in length (GenBank accession number U53446). Predicted DOC-2 protein had a length of 770 amino acids with a molecular weight of 82.5 kDa (Figure 1a ). Homology search showed that DOC-2 shares 81% identity with the mouse p96/mDab2 phosphoprotein (GenBank accession No. U18869) which has been shown to be rapidly phosphorylated in macrophages in response to mitogenic stimulation of CSF-1 (Xu et al., 1995) . Furthermore, the predicted amino acid sequence of DOC-2 is 92% identical and 94% similar to the p96/mDab2 sequence between amino acid residues 1 and 460; and both have multiple SH3 binding motifs at the proline-rich carboxyl terminus of the protein suggesting that DOC-2 is the human homolog of the mouse p96/mDab2 gene product. Further database search identi®ed several DOC-2-related genes including the Drosophila disable (Dab) and its mouse homolog mDab1 which have been demonstrated to be involved in the neuronal development (Howell et al., 1997) . The alignment of all these proteins with DOC-2 shows greatest sequence conservation in an amino-terminal region of 135 residues (Figure 1a and b) . Throughout this region, DOC-2 and p96/Dab2 are 98% identical (Figure 1b) . Moreover, DOC-2 is 66% and 50% identical to mDab1 and Drosophila Dab respectively (Figure 1b ). This stretch of amino acids has been described by Bork and Morgolis (1995) as a phosphotyrosine interacting domain (PID, also known as PTB domain) which has also been identi®ed in proteins such as Shc in human and mouse (Zhou et al., 1995) , and the Numb gene in Drosophila (Uemura et al., 1989) .
Recently, DOC-2 has also been cloned and sequenced from libraries prepared from brain stem and retina (Albertsen et al., 1996) . However, the 5' untranslated region of our DOC-2 sequence is 45 bp longer than the published sequence (Albertsen et al., 1996) . Furthermore, the two sequences dier in six nucleotides and one amino acid. These dierences might be due to polymorphisms among dierent individuals.
Using¯uorescence in-situ hybridization technique, 20 metaphases were analysed. Speci®c hybridization signal was obtained on chromosome 5p13 in all the metaphases suggesting that the DOC-2 gene is located in this region (Figure 2 ). Comparison of the PID region of DOC-2 and related proteins. Alignments were calculated with GCG Pileup, and similar amino acids were boxed with EGCG Prettyplot (threshold 0.8, plurality 3). Per cent identi®es to the DOC-2 PID are indicated at the left Figure 2 Chromosomal localization of the DOC-2 gene on chromosomal spread using a biotin-11-dUTP labeled DOC-2 probe. The hybridization signals were detected on chromosome 5p13 as indicated by the arrows
Western blot analysis and immunohistochemistry
Western blot analysis using an anti-DOC-2 monoclonal antibody generated from amino acid residue 31 to 44 of the DOC-2 protein identi®ed one major 105 kDa protein band and one minor 80 kDa band in all the HOSE cell cultures (Figure 3 ), suggesting that there may be two alternative spliced transcripts which encode these two proteins. We therefore performed RT ± PCR along the full length cDNA using multiple primer sets to evaluate whether there were any alternative spliced formed of DOC-2. One primer set ampli®ed two DNA fragments with size 1045 bp and 391 bp from a region 3' to the PID (data not shown). Direct PCR sequencing showed that a 654 bp fragment from position 787 to 1440 bp was missing ( Figure 1a ). These data suggest that DOC-2 has at least one alternative spliced form with the size of 2634 bp. Several spliced forms have also been identi®ed in the mouse p96/mDab2 protein resulting in the coding for two smaller 67 and 93 kDa proteins (Xu et al., 1995) .
To evaluate the expression pattern of the DOC-2 protein in normal and malignant ovarian tissues in vivo, we performed immunohistochemistry on 13 normal human ovaries, six benign ovarian tumors, 16 borderline ovarian tumors, 20 grade 1, eight grade 2, and 16 grade 3 invasive ovarian carcinomas using the aM2 antibody. Of the 13 normal human ovaries and (Table 1) . Cytoplasmic staining was also found in the epithelial lining of the papillary structures of the borderline tumors. The staining intensity was however signi®cantly lower than those of normal and benign ovarian tumor tissues ( Figure  4a) , with average weighed scores of 3.61 (P50.024) and 1.85 (P50.048) respectively for serous and mucinous borderline ovarian tumors (Table 1) . Most (80%) of grade 1 serous invasive tumors did not show positive staining but all of the mucinous grade 1 tumors were stained by the aM2 antibody with an average weighed score of 4.56 ( Figure 4b , Table 1 ). All grade 2 and grade 3 invasive tumors were negative except the grade 2 mucinous tumors which showed an average weighed score of 5.7 ( Figure 4a , Table 1 ).
Growth kinetic study on DOC-2 transfected ovarian carcinoma cell lines
To evaluate the eect of the endogenous DOC-2 on the growth of ovarian carcinoma cells, we transfected fulllength DOC-2 cDNA in pcDNA3 neo expression vector into ovarian carcinoma cell line SKOV3. Two stable transfected subclones (SKDOC2 ± 36 and SKDOC2 ± 43) were obtained. The presence and the expression of the transfected cDNA in these cell lines were con®rmed by Western and Northern blot analysis. Western blot analysis showed that all the two transfected lines expressed the unspliced 105 kDa DOC-2 protein ( Figure 5 ). Growth curves of three neo transfectants (SKOV3neo1, SKOV3neo2 and SKOV3neo3) and two DOC-2 transfectants were then generated ( Figure 6a ). The growth rate (doubling time) of the neo transfectants was signi®cantly higher than the DOC-2 transfectants. To test the hypothesis that DOC-2 can suppress tumor growth in vivo, we inoculated exponentially growing transfected clones into nude mice at 1610 6 cells per site and followed progression of xenograft formation. SKOV3neo1, 2 and 3 formed xenografts at 30 of 30 inoculation sites. They had exponential growth in the ®rst 15 days. Their growth rate decreased after 15 days and they had another exponential growth after 35 days of inoculation (Figure 6b ). In contrast, both DOC-2 transfectants formed xenografts with 50% of the size of the neo transfectants during the ®rst 15 days and they regressed at the later stages of the experiment.
Discussion
Using RNA ®ngerprinting, we have identi®ed the DOC-2 gene which is preferentially expressed in normal HOSE cells comparing to the ovarian carcinoma cells in vitro and in vivo. Homology search shows that it is a human homolog of the mouse p96/ mDab2, which has been shown to be a novel phosphoprotein rapidly phosphorylated in macrophages in response to mitogen stimulation of CSF-1 (Xu et al., 1995) . DOC-2 and the p96/mDab2 have several characteristics in common. First, both genes are alternatively spliced to generate several transcripts and proteins. Northern blot analysis shows that both proteins have the two major 3.7 kb and 2.9 kb transcripts (Mok et al., 1994 , Xu et al., 1995 . By RT ± PCR, we also demonstrate that the 654 bp spliced fragment from position 787 to 1440 bp of the DOC-2 cDNA corresponds to one of the spliced fragments of p96/mDab2 from position 904 to 1557 bp, which results in the coding of a smaller p67 protein in the mouse (Xu et al., 1995) . Western blot analysis on the HOSE cells showed one major 105 kDa protein band and one minor 80 kDa band. The size of DOC-2 is larger than the predicted 82.5 kDa. This size discrepancy could be due to glycosylation of amino acids or uneven distribution of charges in the protein. Similar phenomenon has also been observed in the mouse p96 protein (Xu et al., 1995) . Figure 5 Western blot analysis on three pCDNA3neo transfected cell lines (SKOV3neo1, 2 and 3) and two DOC-2 transfected lines (SKDOC2 ± 36 and 43) using an anti-DOC-2 monoclonal antibody. An anti-GAP antibody was used on the same blot to normalized protein loading and transfer Second, both DOC-2 and p96/mDab2 contain a highly conserved PID at the amino-terminus suggesting that they may interact with other proteins phosphorylated on tyrosine (Bork and Margolis 1995; Kavanaugh and Williams 1994; Kavanaugh et al., 1995) . Third, the homology between DOC-2 and p96/mDab2 is weakened towards the carboxy-terminus of the protein. They both have proline-rich domains in this region which contains multiple SH3 binding motifs Feng et al., 1994; Sparks et al., 1994; Viguera et al., 1994) . Since Xu et al. (1997) has recently demonstrated that the proline-rich domain of mouse p96/mDab2 can interact with the SH3 domains of Grb2 and reduce the binding between Grb2 and Sos, it will be interesting to examine whether the proline-rich domain of DOC-2 can also interact with these signal transduction molecules in the HOSE cells.
Using Northern blot analysis, we identi®ed high levels of DOC-2 expression in the ovarian surface epithelial cells comprising the germinal epithelium of the ovary. However, other organs including placenta, brain stem, heart, and testis also express signi®cant levels of DOC-2 transcripts (data not shown). Albertsen et al. (1996) has recently identi®ed DOC-2 from a brain stem library and a fetal retina library, and shown DOC-2 expression in three normal tissues and prostate cancer cell lines by RT ± PCR. These ®ndings show that DOC-2 expression is not restricted to the germinal epithelium of the ovary.
We demonstrated down regulation of both DOC-2 transcript (Mok et al., 1994) and protein in ovarian carcinoma cells in vitro. Immunostaining showed high levels of DOC-2 protein expression in the germinal epithelium of the normal ovary and the epithelial lining of the benign ovarian cyst, but the expression levels is signi®cantly lower in borderline ovarian tumors. DOC-2 expression was not observed in high grade serous invasive ovarian carcinomas. These staining patterns suggest that down regulation of DOC-2 may correlate with the malignant potential of the serous ovarian carcinoma cells. Furthermore, in contrast to serous invasive ovarian tumors, all mucinous tumors showed DOC-2 expression. This suggests that down-regulation of DOC-2 may be involved in the development of serous but not mucinous ovarian tumors. Together with our previous ®nding that mucinous tumors have signi®cantly higher K-ras mutational rate than serous tumors (Mok et al., 1993b) , they support the hypothesis that serous and mucinous ovarian tumors may have dierent pathogenesis pathways.
Southern blot analysis showed that the DOC-2 gene is neither lost nor grossly rearranged (data not shown). However, we cannot rule out the possibilities that the down-regulation of DOC-2 in ovarian carcinoma cells is caused by other genetic changes, such as point mutation or changes in methylation status of the DOC-2 promoter. Moreover, reduced DNA-protein interactions of DOC-2 promoter with other trans-acting protein factors may also lead to decreased expression of DOC-2 in ovarian carcinoma cells.
Down-regulation of DOC-2 in serous ovarian carcinoma cells both in vitro and in vivo suggests that DOC-2 may play an important role in growth and dierentiation of the normal ovarian surface epithelial cells and down-regulation of DOC-2 may be involved in the development of serous epithelial ovarian cancers. To evaluate the tumor suppressor role of DOC-2, we isolated stable DOC-2 transfectants and studied the growth kinetics and their ability to form tumors in nude mice. The signi®cantly lower growth rate of the DOC-2 transfected ovarian cancer cells in culture and their inability to form tumors in nude mice suggest that endogenous DOC-2 can suppresss ovarian tumor growth in vitro and in vivo. The tumor suppressor activity may be attributed by the ability of DOC2 to bind and sequester Grb2 from Sos as suggested by Xu et al. (1997) . Down-regulation of DOC-2 in ovarian tumor cells may deregulate Sos-Grb2 binding and contribute to the malignant transformation of the normal ovarian surface epithelial (HOSE) cells (Xu et al., 1997) . Since Sos is a guanine nucleotide exchange (1610 6 ) of SKOV3neo1, 2 and 3; and SKDOC2 ± 36 and 43 were subcutaneously inoculated behind the anterior forelimb of 4-week-old athymic nude mice (nu/nu). Tumors were measured externally on the indicated days in two dimensions using a caliper. Volume was determined from the equation: V=(L6W 2 )60.5, where L is length and W is width of the tumor. Each point represents an average volume of at least eight xenografts factor for Ras (Chardin et al., 1993) , it will be of interest to evaluate whether down-regulation of DOC-2 may lead to Ras activation which results in HOSE cells transformation.
Materials and methods
cDNA cloning and sequence analysis of DOC-2
The full length DOC-2 cDNA was cloned by using the marathon cDNA ampli®cation system (Clontech lab. Inc., Palo Alto, CA). Total RNA was ®rst isolated from a normal ovarian surface epithelial cell culture by a standard guanidinium thiocyanate-cesium chloride method (Chirgwin et al., 1979) . First strand cDNA synthesis was performed using 1 mg total RNA and an anchor primer with degenerate nucleotides at base of poly-A tail in a total volume of 10 ml. After 1 h incubation at 428C, 10 ml was removed from the ®rst-strand reaction mix and used for second-strand cDNA synthesis. The second-strand reaction mix was incubated at 168C for 90 min and subsequently puri®ed by phenol-chloroform extraction method. The double strand cDNA was then precipitated with ethanol and resuspended in 10 ml of water. Adaptor ligation was then performed at 168C overnight using 5 ml ds cDNA and a marathon cDNA adaptor. The adaptor ligated cDNA was then diluted with Tricine-EDTA buer to a ®nal volume of 100 ml which was subsequently used for the rapid ampli®cation of 5' and 3'-cDNA ends (5' and 3'-RACE). A sense primer (5'-CGGGTGTTGACCAGATG-GATTTGTTTGGGG-3') and an antisense primer (5'-CGTCACGGAAAGGATCAGGATTAGGGGTGG-3') derived from the partial DOC-2 cDNA sequence (Wong et al., 1993) were used to performed 3' and 5' RACE respectively. The 3' and 5' RACE PCR products were then subjected to another round of PCR reaction using a nested sense primer (5'CGGCATCACCTCCTGTTCTC-TTCC-3') and an intense primer (5'-TGGGAAAGA-AGTTGAGATTGGCAG-3'). The PCR products were puri®ed on a 1% agarose gel in TAE buer. DNA was then eluted from the gel and cloned into pBluescript KS+ by blunt end ligation into the EcoRV site. Clones were partially sequenced using vector primers. A full length clone was generated by cross-PCR from the 3' and 5' RACE clones using one primer (5'-TCGCTTCACG-GAGGCAATAG-3') at the 5'-end and another primer (5'-GAAAAAAAGGGGAGGAGAG-3') at the 3'-end. The full length DOC-2 cDNA was subsequently cloned in the pCRscript vector (Stragagene, La Jolla, CA) for sequencing using the ABI377 automatic sequencer.
Chromosomal localization
Full length DOC-2 cDNA in pCRscript vector was ®rst labeled with biotin-11-dUTP using nick-translation. Chromosome spreads were prepared from PHA-stimulated peripheral blood lymphocytes from donors using methotrexate synchronization method as described by Yunis 1976 . For in-situ hybridization, chromosome preparations were denatured in 70% formamide-26SSC at 708C for 2 min and cooled in 70% ethanol at 7208C. After dehydration and air-drying, 30 ml of denatured (758C for 10 min) hybridization mixture (50% formamide, 26SSC, 10% dextran sulfate, 0.1 mg/ml salmon sperm DNA, and 5 ng/ml of labeled DNA) was layered per slide. Coverslips were applied and sealed with rubber cement, and the hybridization was carried out for 15 h at 378C. Posthybridization washes were in 50% formamide-26SSC at 428C (365 min each) and in 0.16SSC at 608C (365 min each). Biotin-labeled DNA was detected using FITCconjugated avidin DCS (5 mg/ml) (Vector Laboratories).
Digital images were captured using a Zeiss Axioscop epi¯uorescence microscope equipped with a cooled charged-coupled (CCD) camera (Photometrics).
Western blot analysis
For preparation of protein lysates, cells were ®rst washed three times with phosphate buered saline (PBS) with 1% vanadate, lysed in Lammaeli's lysis buer (1% Tritin-100, 21 mg/ml aprotinin, 1 mM phenylmethylsulfonyl¯uoride, 0.5 mg/ml leupeptin, 4.9 mM MgCl 2 , and 1 mM vanadate in PBS) and then centrifuged. The Micro BCA Protein Assay Kit (Pierce) was used for protein quantitation. Cell lysates (25 mg of each sample) were diluted with 26SDS sample buer (125 mM Tris, 2.2 M glycerol, 1.42 M b-mercaptoethanol, 160 mM SDS, 10 mg/L bromophenol blue, pH 6.8), boiled for 10 min, and analysed by SDS ± PAGE (8%). Polypeptides were then transferred to Immobilon-P membrane (Millipore) and incubated with 5% dry milk overnight. The membrane was washed with PBS-0.1% Tween 20 (Sigma) and incubated with a monoclonal antibody generated against a synthetic peptide (GSEKT-DEYLLARFKG) (Transduction Laboratories, Lexington, KY) for 1 h. After washing with PBS-0.1% Tween 20, the membrane was incubated with horseradish peroxidaseconjugated donkey anti-mouse IgG (Amersham) for 1 h. Signals were visualized using the ECL Chemiluminescence System (Amersham).
Immunohistochemistry
Localization of the DOC-2 protein by immunohistochemistry was performed using the aM2 antiserum raised against a synthetic peptide (IDEKTGVIEHEHPVNKIS) (Xu et al., 1995) . Archived paran blocked tisues including 13 normal human ovaries, six benign ovarian tumors, 16 borderline ovarian tumors (14 serous and two mucinous); and 20 grade 1 (15 serous and ®ve mucinous), eight grade 2 (six serous and two mucinous), and 16 grade 3 serous invasive ovarian carcinomas were used. Five micrometer sections were cut, mounted on Superfrost/Plus microscopic slides (Fisher Scienti®c, Pittsburgh, PA), and incubated at 508C overnight. The sections were then transferred to phosphate buered saline (PBS) and quenched in 0.2% H 2 O 2 for 20 min. After quenching, the sections were washed in PBS for 20 min, incubated with normal horse blocking serum for 20 min and subsequently incubated with the aM2 polyclonal antibody (1 : 4000) at room temperature for 1 h. After incubation, the sections were washed in PBS for 10 min, incubated with diluted biotinylated secondary horse anti-rabbit antibody solution for 30 min, and washed again in PBS for 10 min. After washing, the sections were incubated with ABC reagent (Vector, Burlingame, CA) for 30 min, washed in PBS for 10 min, incubated in diaminobenzidine (DAB) solution for 5 min and washed in water for 10 min. The sections were then counterstained with hematoxylin, dehydrated with an ascending series of alcohol, cleared in xylene and mounted in Permount (Fisher Scienti®c, Pittsburgh, PA). The speci®city of the staining was evaluated and con®rmed by preabsorbing the antibody with the puri®ed peptide (60 mg/ml, Gynosys) for 2 h at 378C before applying to the sections. Five to seven sections were randomly taken from each block and were examined by two independent observers. The positive cells were quanti®ed as the percentage of the total number of cells and were scored on a 5-point scale: 0, 55%; 1, 5 ± 25%; 2, 25 ± 50%; 3, 50 ± 75%; and 4, 475%. The intensity of staining was noted by a semi-quantitative 3-point scale: 1, weak; 2, moderate; and 3, intense. A weighted score for each tumor specimen was produced by multiplying the percentage score with the intensity score. Data were then analysed by one tailed one sample t-test. Signi®cantly dierence was considered when P50.05.
Isolation of stable DOC-2 transfected ovarian carcinoma cell lines
The full length DOC-2 cDNA (3.2 kb) was released from the KpnI and NotI cloning site from the pCRscript vector (Stratagene, La Jolla, CA) and inserted into the pCDNA3neo eukaryotic expression vector (Invitrogen, La Jolla CA) in the sense orientation. The construct was then transfected into the recipient cells SKOV3 by calcium phosphate precipitation method. For control experiments, the vector pCDNA3neo was also transfected into SKOV3. All the transfected cells were subjected to G418 (500 mg/ml, BRL, Gaithersburg, MD) selection. Resistant clones representing the stable transfected cells were ring-cloned and expanded. The expression of DOC-2 in the stable transfected cells were examined by RT ± PCR and Western blot analysis.
Growth kinetic and tumorigenicity study
For in vitro growth kinetic study, three pCDNA3neo transfected SKOV3 cells (SKOV3neo1, 2 and 3) and two DOC-2 transfected SKOV3 cells (SKDOC2±36 and SKDOC2 ± 43) were plated in 96-well culture plates at 1610 3 cells/100 ml/well. 2, 4, 6 and 8 days after plating, cells were washed and then stained with 0.5% crystal violet in 20% methanol. The absorbance at 595 nm was measured after the cells were lysed with 1% acetic acid in 50% ethanol. For tumorigenicity study, 1610 6 SKOV3 transfectants were inoculated behind the anterior forelimb of 4-week-old athymic mice (athymic nu/nu). Each mouse was inoculated on both sides. Each group consisted of 5 mice and were maintained in a pathogen-free facility for 60 days. Growth curves for xenografts were determined by externally measuring tumors in two dimensions using a caliper. Volume (V) was determined by the following equation as described (Sun et al., 1994) , where L is length and W is the width of the xenograft: V=(L6W 2 )60.5.
